ICU Medical, Inc. $ICUI Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC trimmed its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 15.4% during the first quarter, Holdings Channel.com reports. The fund owned 224,163 shares of the medical instruments supplier’s stock after selling 40,832 shares during the period. Segall Bryant & Hamill LLC’s holdings in ICU Medical were worth $28,951,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ICUI. Norges Bank purchased a new position in shares of ICU Medical during the 4th quarter worth approximately $58,083,000. F m Investments LLC increased its holdings in ICU Medical by 33.3% in the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after purchasing an additional 11,608 shares during the last quarter. Kirr Marbach & Co. LLC IN raised its position in ICU Medical by 18.4% in the first quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock valued at $5,702,000 after purchasing an additional 6,863 shares during the period. Thrivent Financial for Lutherans raised its position in ICU Medical by 1,604.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares during the period. Finally, Vanguard Group Inc. lifted its stake in ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after purchasing an additional 89,755 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a research report on Monday, June 15th. KeyCorp boosted their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research note on Wednesday, May 27th. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $172.00.

ICU Medical Price Performance

Shares of ICUI opened at $168.51 on Friday. The company has a market cap of $4.21 billion, a P/E ratio of 91.09, a PEG ratio of 2.35 and a beta of 0.76. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $170.81. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average price is $148.01 and its 200 day moving average price is $140.30.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million during the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The firm’s revenue was down 12.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, research analysts forecast that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.